Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
OncoZenge AB logo — Potential to be the leading treatment for oral pain.

OncoZenge AB

Potential to be the leading treatment for oral pain.

Founded 2020 Sweden Sweden 4 employees Seed Total: $10.00M Biotechnology, Health Care +1

General Information

Company Name OncoZenge AB
Founded Year 2020
Location Sweden Sweden
Employees 4
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with OncoZenge AB. To contact OncoZenge AB, visit oncozenge.se.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OncoZenge AB compare?

A PDF of OncoZenge AB and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OncoZenge AB soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OncoZenge AB

OncoZenge AB has the potential to become a leading player in the treatment of oral pain, as suggested by its slogan – "Potential to be the leading treatment for oral pain." The Swedish pharmaceutical company, established in 2020, is focused on developing a novel treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's leading product candidate is BupiZenge®. OncoZenge AB operates in the biotechnology, healthcare, and pharmaceutical industries and is headquartered in Sweden. The company recently secured a significant investment of kr10.00M in a Venture Round on 16 November 2020. The funding came from investors Linc AB and Ostersjöstiftelsen. This injection of capital could fuel OncoZenge AB's pioneering work in addressing oral pain associated with cancer treatment, potentially bringing much-needed relief to patients in the future. As the company continues to advance its product development and clinical trials, this recent investment underscores the confidence that key investors have in OncoZenge AB's potential to make a meaningful impact in the healthcare space.

Business keywords: OncoZenge, Swedish pharmaceutical company, Oral pain treatment, Radiation therapy, Chemotherapy, Cancer patients, BupiZenge, Pain relief, Medical innovation, Oncology treatment, Pharmaceutical development

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round kr10.00M 2
Linc AB
Linc AB, Ostersjöstiftelsen
16 Nov 2020

OncoZenge AB Alternatives & Competitors

View All Alternatives
OncoZenge AB vs
Humed Technologies, Inc.
Humed Technologies, Inc. United States

HuMed Technologies is a cancer support company developing products that alleviate adverse effects of...

1 employees
Biotechnology, Health Care
OncoZenge AB vs
Cooler Heads Care
Cooler Heads Care United States

Preserve identity, agency, and privacy by reducing chemo-related hair loss.

Series A
43 employees
Biotechnology, Health Care
OncoZenge AB vs
Cavion
Cavion

Empowering therapies for cancer and neurologic diseases through pioneering ion channel inhibition

Series A
Biotechnology, Health Care
View all alternatives

FAQ About OncoZenge AB

Potential to be the leading treatment for oral pain.
OncoZenge AB was founded in 2020.
OncoZenge AB is headquartered in Sweden.
OncoZenge AB operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on OncoZenge, Swedish pharmaceutical company, Oral pain treatment and Radiation therapy.
OncoZenge AB has approximately 4 employees.
OncoZenge AB has completed 1 funding round, raising a total of $10.00M. The latest funding stage is Seed.
Top alternatives and competitors to OncoZenge AB include Humed Technologies, Inc., Cooler Heads Care, Cavion, Cleveland Biolabs, ViewRay, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OncoZenge AB and Humed Technologies, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OncoZenge AB, https://bouncewatch.com/company/oncozenge-ab, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes